USGrantedMethod of treatment

R-ketamine and its use as a pharmaceutical

US-10406121-B2

Bibliographic data

Patent number: US-10406121-B2
Jurisdiction: US
Status: Granted
Type: Method of treatment
Priority date: 13 September 2013
Filing date: 21 December 2017
Grant date: 10 September 2019

Compounds claimed

Arylcyclohexylamine

Assignees

Perception Neuroscience

Perception Neuroscience is a New York–based biopharmaceutical subsidiary of atai Life Sciences developing PCN-101 (arketamine, R-ketamine) as a potentially safer, lower-dissociation alternative to racemic ketamine for treatment-resistant depression. The company completed a Phase 1 single-ascending-dose study in 58 healthy volunteers and a Phase 2a double-blind, placebo-controlled trial in TRD patients, with a collaboration with Otsuka Pharmaceutical for the Japanese market.